Characterization of the Necrotic Protein That Regulates the Toll-mediated Immune Response in Drosophila*

Andrew S. RobertsonDagger §, Didier Belorgey, Kathryn S. Lilley||, David A. Lomas, David GubbDagger , and Timothy R. Dafforn**DaggerDagger

From the Dagger  Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, United Kingdom, the Departments of ** Haematology and  Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/Medical Research Council Building, Hills Road, Cambridge, CB2 2XY, United Kingdom, and || Cambridge Centre for Proteomics, Department of Biochemistry, University of Cambridge, Downing Street, Cambridge CB2 1QW United Kingdom

Received for publication, September 10, 2002, and in revised form, October 30, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Necrotic (Nec) is an important component of the proteolytic cascade that activates the Toll-mediated immune response in Drosophila. The Nec protein is a member of the serpin (SERine Protease INhibitor) superfamily and is thought to regulate the cascade by inhibiting the serine protease Persephone. Nec was expressed in Escherichia coli, and the purified protein folded to the active native conformation required for protease inhibitory activity. Biochemical analysis showed that Nec had a broad inhibitory specificity and inhibited elastase, thrombin, and chymotrypsin-like proteases. It did not inhibit trypsin or kallikrein. These data show that Necrotic is likely to inhibit a wide range of proteases in Drosophila and that Nec has the specificity requirements to act as the physiological inhibitor of Persephone in vivo.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The mammalian and insect innate immune responses are conducted through highly conserved intracellular signaling cascades that allow the host to deliver an efficient, rapid, and potent counterattack against invading microorganisms (1-5). However, while mammalian systems are primarily activated through Toll-like receptor 4 (TLR4),1 which directly recognizes and binds microbial molecules (see Fig. 1a), the Drosophila innate immune response is initiated through pattern recognition proteins circulating in the Drosophila hemolymph (see Fig. 1b) (6). Recognition of molecules such as peptidoglycan and lipopolysaccharide in the hemolymph initiates an extracellular serine protease cascade, resulting in the cleavage and activation of the Toll ligand, Spätzle (Spz) (6). This serine protease cascade is tightly regulated by the protease inhibitor, Necrotic (Nec) (also known as Spn43Ac) (7, 8).

Nec is a member of the serpin (SERine Protease INhibitor) superfamily (7, 8). nec null mutants result in constitutive expression of the antifungal Toll target gene, Drosomycin, similar to that seen in Toll gain of function alleles, and show Spz predominantly present in its cleaved form (8). Furthermore, in flies containing nec;Tl or nec;spz double mutations, Drosomycin is not induced in the absence of immune challenge (8). Recently, mutations in the catalytic triad of Persephone (Psh), a member of the serine protease family, were discovered to suppress the nec mutant phenotype and activate the Toll pathway (9), confirming that Toll activation is mediated through at least one serine protease, which is in turn regulated by Nec.

Members of the serpin superfamily of proteins are involved in the regulation of a large number of processes including coagulation (antithrombin), the acute phase response (alpha 1-antitrypsin (alpha 1AT) and alpha 1-antichymotrypsin (alpha 1ACT)), and tissue repair (plasminogen activator inhibitor-1 (PAI-1)) (10). The mechanism of serpin-dependent protease inhibition requires that the serpin reactive center loop (RCL) be presented as an ideal substrate for its target protease (11). The protease binds and cleaves a peptide bond at the P1-P1' position of the RCL (12). Cleavage results in an SèR (stressed to relaxed) conformational change caused by the rapid insertion of the RCL into a central 5-stranded beta -sheet (Sheet A). This rapid loop-sheet insertion takes place before the deacylation step can be completed, thereby drawing the covalently attached protease to the opposite pole of the serpin molecule (13-15). The result is a distortion of the catalytic site of the protease and its entrapment in a covalently linked serpin-protease complex. Besides cleavage of the RCL, a stable 6-stranded A-sheet can be formed by two other conformational changes in the serpins. These forms are denoted the latent (16) and the polymeric conformations (17-19). The RCL of the latent serpin is inserted into the A sheet without cleavage, whereas the polymeric is characterized by the sequential incorporation of the RCL of one serpin into the A sheet of another. Both forms are inactive as inhibitors, and mutations that favor these conformations are associated with a wide variety of diseases (20).

Sequence alignments against serpins of known structure and function show that Nec has an Ala-rich hinge region and a predicted P1-P1' Leu-Ser active site, suggesting it has an inhibitory profile similar to that of alpha 1-antichymotrypsin (Fig. 1c) (7). Nec also has an 88-100-residue-long N-terminal extension that is unusual among serpins. The extension contains regions rich in glutamines and prolines, including a 24-residue polyglutamine repeat of unknown function (7).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 1.   The mammalian (a) and Drosophila (b) Toll-mediated innate immune response are conserved intracellularly but are activated through different mechanisms. In mammalian systems, the microbial sugar lipopolysaccharide (LPS) binds directly and activates the Toll-like receptor 4 (TLR4) in conjunction with the co-receptor CD14. Activation of TLR4 initiates a secondary messenger system involving the adapter proteins MyD88 and IRAK, resulting in the degradation of Ikappa B and allowing the NF-kappa B transactivator to enter the nucleus and activate expression of anti-microbial peptide (AMP) genes. In Drosophila, fungal and Gram-positive bacterial infection results in activation of pattern recognition molecules (PRM), such as peptidoglycan recognition protein (PGRP), circulating in the hemolymph. These activated molecules activate a serine protease(s), such as Psh, which result in the cleavage and activation of the Toll ligand, Spz. Activated Spz (Spz*) signals through the Toll (Tl) receptor, initiating an intracellular secondary messenger cascade very similar to that of the mammalian system and involving the MyD88 homologues Tube (Tub) and dMyD88, the IRAK homologue Pelle (Pll), the Ikappa B homologue Cactus (Cact), and the NF-kappa B homologue (DIF). Degradation of Cact allows the DIF transactivator to then enter the nucleus, where it can induce the expression of target antimicrobial peptides. c, a model of the native conformation of Necrotic showing the 5-stranded beta -sheet A (green) and beta -sheet B (yellow) that are required for structural stability, the RCL (red), and the N-terminal extension (cyan) leading into the alpha -helix A (blue) of the core serpin structure. The Leu-Ser P1-P1' residues of the RCL are indicated.

The purpose of this study is to define the conformation and inhibitory profile of Nec. To achieve this we have expressed and characterized the recombinant protein. Using this material we have been able to show that Nec acts as a potent elastase inhibitor but also strongly inhibits the activity of thrombin and chymotrypsin. Nec does not inhibit trypsin and kallikrein. Thus, Nec is likely to have a broad inhibitory specificity in the fly and is potentially responsible for the inhibition of multiple proteases. Additionally, Psh, which has a thrombin-like S1 architecture, is likely to be inhibited by Nec in vivo.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Materials-- Restriction enzymes were purchased from Roche Molecular Biochemicals, T4 DNA-ligase was purchased from New England Biolabs (Hitchin, Hertfordshire, UK), and oligonucleotides were synthesized at Sigma. The IMPACT-NT protein purification system was purchased from New England Biolabs. Porcine pancreatic trypsin, bovine pancreatic alpha -chymotrypsin, porcine pancreatic kallikrein, porcine pancreatic elastase (PPE), and bovine serum thrombin were purchased from Sigma. Human neutrophil elastase (HNE) was purchased from Athens Research and Technology (Athens, GA). The chymotrypsin substrate N-succinyl-Ala-Ala-Pro-Phe-para-nitroanilide, the trypsin and kallikrein substrate N-benzoyl-DL-arginine-para-nitroanilide, and the PPE/HNE substrate N-methoxy-Ala-Ala-Pro-Val-para-nitroanilide were purchased from Sigma. The thrombin substrate, S-2238 (H-D-Phe-pipecolyl-Arg-para-nitroanilide) was from Chromogenix (Quadratech, Epsom, UK). The rabbit anti-nec antibody was a kind gift from Dr. J.-M. Reichhart, Université Louis Pasteur, Strasbourg, France.

Protein Purification-- Expression and purification of Nec was achieved by fusion with an N-terminal tag consisting of a chitin binding domain and a protein splicing element (Intein). The Intein sequence undergoes specific self-cleavage in the presence of thiols, such as cysteine or DTT, allowing separation of the target protein from the chitin-bound affinity tag. The Nec sequence with (Nec) and without (Nec-Delta N) the N-terminal extension was amplified using PCR from nec cDNA (7) and cloned into the INTEIN pTYB12 expression vector using SpeI and NotI restriction sites. Escherichia coli BL21(DE3) cells containing the pTYB12-Nec-Delta N construct were induced at an OD of 0.5-0.6 with 0.1 mM isopropyl-1-thio-beta -d-galactopyranoside and grown overnight at 23 °C. Cells were harvested by centrifugation, resuspended in 20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1 mM EDTA, and lysed by sonication in the presence of a mixture of protease inhibitors (Sigma). Lysis extracts were isolated by high speed centrifugation and then applied to a column containing the IMPACT-NT chitin-resin. On-column self-cleavage of the INTEIN sequence was carried out by overnight incubation with 50 mM DTT at 4 °C. The protein was further purified through a Superdex 200 gel filtration column in 100 mM Tris-HCl, pH 7.4 (Amersham Biosciences).

Circular Dichroism (CD)-- CD experiments were performed using a JASCO J-810 spectropolarimeter in 100 mM Tris-HCl, pH 7.4, at 25 °C. Thermal unfolding experiments were performed by monitoring the CD signal at 216 or 222 nm between 25 and 95 °C using a heating rate of 1 °C/min at a concentration of 0.2 mg/ml in a 0.05-cm pathlength cuvette. The TM was calculated through regression analysis as detailed previously (21). The results were the mean of three independent experiments.

Complex Formation Assays-- Recombinant Nec protein was incubated with varying amounts of serine proteases for 15 min at room temperature in 50 mM Hepes, 150 mM NaCl, 0.01% w/v dodecyl-maltoside, pH 7.4. The reactions were stopped through incubation with 1% w/v SDS-PAGE loading buffer and boiling for 3 min. The samples were pulse-centrifuged and then immediately run on a 10% w/v SDS gel, and the protein was visualized by staining with Coomassie Blue.

Determination of Reaction Parameters Describing Protease Inhibition-- The inhibition rate constant (ka) for Nec was determined for all serine proteases except thrombin under pseudo-first order conditions (i.e. [I>=  10[E]0) using the progress-curve method (22, 23). Rate constants of inhibition were measured at 25 °C in 50 mM Hepes, 150 mM NaCl, 0.01% w/v dodecyl-maltoside, pH 7.4, by adding the enzyme (20 nM final) to a mixture of Nec protein (from 200 to 800 nM) and the appropriate substrate (1 mM) and recording the release of product as a function of time. The progress curves were then analyzed according to Equation 1 (22, 23).
[P]=v<SUB>s</SUB>t+<FR><NU>v<SUB>z</SUB>−v<SUB>s</SUB></NU><DE>k<SUB>obs</SUB></DE></FR>(1−e<SUP>−k<SUB>obs</SUB>t</SUP>) (Eq. 1)
where vz is the initial velocity, vs is the steady-state velocity at completion of the reaction, and kobs is the pseudo-first rate order rate constant for the approach toward steady state. The values of each variable were obtained by fitting the progress curve to Equation 1 using nonlinear regression analysis and were then used to calculate ka according to Equation 2 under the assumption that the inhibition takes place through a simple bimolecular reaction.
k<SUB>obs</SUB>=<FR><NU>k<SUB>a</SUB>[I]<SUB>o</SUB></NU><DE>1+[S]<SUB>0</SUB>/K<SUB>m</SUB></DE></FR>+k<SUB>d</SUB> (Eq. 2)
The association rate constant (ka) for thrombin was determined by reacting thrombin and Nec for different periods of time before addition of substrate, which slows down the association process enough to allow measurement of residual enzyme activity. Pseudo-first order conditions were used, and the data fitted to the following exponential equation (17, 24).
[E]=[E]<SUB>0</SUB> · e<SUP>−k<SUB>a</SUB>[I]<SUB>o</SUB>t</SUP> (Eq. 3)
where [E] is the concentration of free enzyme at any time, t and [E]0 is the concentration at t = 0. [E]0 and [E] are proportional to the rate of substrate hydrolysis at t = 0 and at any time t, respectively. ka was calculated from the pseudo-first order rate constant ka[I]o.

Transverse Urea Gradient (TUG) PAGE-- TUG PAGE was carried out using 7.5% w/v polyacrylamide gels as detailed previously. Twenty-five µg of Nec protein was loaded on each gel and visualized with silver staining.2

Protein Identification by Mass Spectrometry-- Proteins within excised gel pieces were digested to peptide fragments by modified trypsin (Promega) using a Micromass MassPrep Station. 6.4 µl (~50% of total) of the digestion supernatant was applied to a Micromass quadrupole-time-of-flight/capillary liquid chromatography system for liquid chromatography/tandem mass spectrometry analysis. Peptide separation occurred using a PepMapC18 180 µm internal diameter, 15-cm length capillary liquid chromatography column (LC Packings/Dionex San Francisco, CA). Identification of the peptides analyzed was carried out searching with uninterpreted fragmentation data using MASCOT (Matrix Science Ltd., London, UK).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Expression and Purification of Necrotic Protein-- Initial attempts to express full-length Nec resulted in no detectable protein, possibly due to secondary structure within the GC-rich mRNA region coding for the poly-Q tract. A new truncated gene was constructed containing the serpin core structure but without the first 99 residues of the N terminus (Nec-Delta N). The residues "Ala-Gly-His-Met-Thr" were added to the N terminus of the Nec-Delta N protein as a result of fusion to the chitin-binding protein so that the N terminus of the recombinant protein is AGHMTPPPVF (Fig. 2a). Nec-Delta N eluted from the chitin column at ~90% purity after overnight cleavage with DTT as determined by SDS-PAGE (Fig. 2b). The protein was further purified using Superdex 200 gel filtration to remove low molecular mass contaminants and protein aggregates (Fig. 2c), producing a final yield of 3 mg of pure monomeric Nec-Delta N per 6 liters of culture. The identity of Nec-Delta N was confirmed by Western blot analysis using an antibody to Nec protein (not shown). Moreover, matrix-assisted laser desorption ionization mass spectrometric analysis produced 47 peptide matches covering 45% of the Nec sequence.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   a, a schematic showing the full-length (top) and Delta N (bottom) Nec proteins. The N-terminal extension containing the poly-Q tract is indicated in the full-length protein. The Nec-Delta N schematic also shows the N-terminal chitin binding tag, along with additional residues added as a result of the cloning strategy. The predicted start of the core protein, residues PPPVF, is indicated in both as is the position of the P1-P1' residues of the RCL. b, 10% w/v SDS-PAGE of the purification of Nec-Delta N. Lane 1, molecular mass protein markers (kDa). Lane 2, a crude extract of BL21 (DE3) cells expressing Nec-Delta N. Lane 3, protein eluted from the chitin column after overnight incubation with 50 mM DTT. Lane 4, 5 µg of purified Nec-Delta N following separation on a Superdex 200 gel filtration column in 100 mM Tris-HCl, pH 7.4. c, chromatogram showing the separation of Nec-Delta N after chitin affinity purification on a Superdex 200 gel filtration column. A single peak at ~40 kDa confirms that Nec-Delta N is in monomeric conformation. Molecular mass standards are indicated at the top of the chromatogram.

Characterization of Nec-Delta N-- Stability studies conducted on the purified protein revealed that Nec-Delta N was folded and contained alpha -helix and beta -sheet secondary structures characteristic of serpins (Fig. 3a). Protein stability measurements made using circular dichroism revealed a loss of secondary structure at 222 nm at 48.4 ± 0.7 °C (Fig. 3b). To test whether RCL cleavage resulted in a stable, relaxed species, trypsin-cleaved Nec-Delta N was analyzed by TUG electrophoresis. Nec-Delta N was incubated with porcine pancreatic trypsin at an enzyme to serpin molar ratio of 1:500 in buffer A (50 mM Hepes, 150 mM NaCl, 0.01% w/v dodecyl-maltoside, pH 7.4) for 15 min at 22 °C. The resulting protein had a migration profile on 10% w/v SDS-PAGE characteristic of a RCL-cleaved serpin. Assessment by TUG-PAGE revealed two different profiles: a classic "S" curve, representative of the gradual unfolding that is characteristic of a native serpin, and a species that was stable at higher urea concentrations, indicative of partial or complete loop insertion into beta -sheet A (Fig. 3c). These results demonstrate the stressed to relaxed transition required for the serpin inhibitory mechanism. Taken together, these data are typical of serpins in their native monomeric conformation as opposed to the latent, RCL-cleaved or loop-sheet serpin polymers and suggest proper folding of recombinant Nec-Delta N.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   a, CD spectra of Nec-Delta N (solid) showing the presence of mixed alpha -helix and beta -sheet secondary structure, consistent with the known common core structure of a serpin. This figure is representative of three independent experiments carried out in 100 mM Tris-HCl buffer, pH 7.4, at 25 °C. The CD spectra of alpha 1-antitrypsin (dashed) is also included for comparison. Thermal (b) and chemical (c) unfolding of Nec-Delta N showing a single transition at 48.4 °C with a standard deviation of 0.7 °C and ~3 M urea respectively, indicating that Nec-Delta N is in the native conformation. Thermal stability was assessed by measuring the changes in protein secondary structure using the CD signal at 222 nm, with respect to temperature. Chemical unfolding was determined by a 7.5% w/v TUG gel electrophoresis using a 0- to 8-M urea gradient. The profiles of native and cleaved Nec-Delta N are indicated. Both of these figures are representative of at least three independent experiments performed in 100 mM Tris-HCl buffer, pH 7.4.

Protease Inhibition by Nec-Delta N-- Serpin inhibition results in a stable serpin-protease complex joined through an ester linkage between the P1 residue from the serpin RCL and the catalytic serine from the protease. To test for potential inhibitory activity, Nec-Delta N was incubated with a select panel of serine proteases: bovine pancreatic alpha -chymotrypsin, HNE, PPE, bovine serum thrombin, porcine pancreatic trypsin, and porcine pancreatic kallikrein. Formation of a covalently linked serpin-protease complex was observed as a cathodal band shift on a 10% w/v SDS-PAGE. Nec-Delta N forms complexes with the thrombin, neutrophil elastase, pancreatic elastase, and chymotrypsin after a 15-min incubation at 22 °C (Fig. 4). Increasing serpin concentration while the protease concentration remained constant showed an increase in the complex band at 60-70 kDa and the cleaved serpin at 35-40 kDa coupled with a decrease of native Nec-Delta N. The identity of these bands was confirmed for the Nec-thrombin reaction using mass spectrometric analysis with the complex band yielding 37 peptides matching 34% of the Nec sequence and 19 peptides matching 21% of the thrombin sequence. The cleaved band produced 36 peptides covering 34% of the Nec sequence. The other minor bands observed are most likely due to degradation of major species by uninhibited protease.


View larger version (106K):
[in this window]
[in a new window]
 
Fig. 4.   10% w/v SDS-PAGE showing the interaction of Nec-Delta N with a panel of six proteases. E denotes lanes containing only protease, and lanes marked 1:1 and 1:4 signify differing protease to serpin molar ratios. N and C denote native and cleaved serpin bands respectively. * indicates the SDS-stable protease-serpin complexes.

In contrast, Nec-Delta N failed to form a complex with trypsin and kallikrein. Comparison of 15-min incubations using 1:1 and 1:4 enzyme to serpin molar ratios showed an increase in Nec-Delta N degradation as more serpin was added and no complex formation. Experiments in which the trypsin and kallikrein concentration was increased and Nec-Delta N kept constant (enzyme to serpin molar ratios of 1:0.02, 1:0.16, 1:0.8, 1:4, and 1:20) resulted in increased Nec degradation in association with increased enzyme and no complex formation. Finally, an incubation of 1:0.16 Nec to enzyme molar ratio at 22 °C that was stopped at 10, 15, and 20 min by boiling in 1% w/v SDS buffer showed an increase in Nec degradation over time and no complex formation. This repeated failure to form an inhibitory complex between Nec-Delta N and the proteases trypsin and kallikrein show that Nec-Delta N is not an active inhibitor of these serine proteases.

Inhibition Kinetics of Nec-Delta N-- The kinetics of Nec-Delta N inhibition was further examined through the determination of both the association rate constant (ka) and the stoichiometry of inhibition (SI) values for each protease from the panel. Each reaction was conducted at room temperature (22 °C) in buffer A. ka values for all proteases except thrombin were determined under pseudo-first order conditions using the progress curve method and were repeated at least three times over a range of concentrations of Nec-Delta N (between 100 and 800 nM) and 20 nM enzyme in the presence of excess substrate (1 mM) (Fig. 5). The thrombin association rate constant was determined under pseudo-first order conditions using the discontinuous method, where enzyme and inhibitor were preincubated for varying amounts of time before substrate is added using time points of 0, 3, 5, 10, 15, 25, and 35 min. The results showed that the interaction between Nec-Delta N and elastase-like proteases was the most rapid (Table I), with ka values of 1.1 × 105 M-1 s-1 for HNE and 5.7 × 105 M-1 s-1 for PPE. Rapid association constants of chymotrypsin and thrombin with Nec-Delta N were also observed, with ka values of 4.4 × 104 M-1 s-1 and 1.0 × 104 M-1 s-1, respectively. The SI values showed that a 1:1 Nec-Delta N to enzyme ratio is sufficient for complete inhibition of HNE, while higher concentrations of the serpin are needed for total inhibition of PPE (SI = 2.2), chymotrypsin (SI = 2.0), and thrombin (SI = 4.4). In contrast the ka and SI values for the interaction between trypsin and Nec-Delta N, and kallikrein and Nec-Delta N, could not be measured as no inhibition of protease was observed.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 5.   Progress curve of Nec-Delta N inhibition of HNE. 20 nM of enzyme was added to a mixture of 1 mM substrate and various concentrations of Nec-Delta N (solid line, 100 nM; dashed line; 200 nM; dotted line, 400 nM), and release of product (y-axis) was recorded over time (x-axis).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetic constants for inhibition of a panel of serine proteases by Nec-Delta N
Errors for the analysis of the kinetic parameters are <10%. The results represent the mean of three independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The aim of this study was to determine the biochemical characteristics of the serine protease inhibitor Nec. Nec plays a central role in the control of a proteolytic cascade responsible for modulating the innate immune response in Drosophila. Nec was identified as a regulator of the cascade through analysis of necrotic gene knockouts (8). Nec is a member of the serpin superfamily but differs from other serpins in having a novel N-terminal extension containing a glutamine-rich sequence. This extension abolished protein expression in E. coli, resulting in the need to prepare a shortened construct (Nec-Delta N) that contained only the common serpin core. The design of the construct was based on homology with antithrombin (25) and alpha 1-antichymotrypsin (13). A few other inhibitory serpins contain an N-terminal extension, but none are as extensive as that found in Necrotic. These include antithrombin and heparin cofactor II; in the former case the extension is involved in forming a heparin binding site (26), whereas in the later it provides an additional protease binding site (27). The N terminus of Nec has little sequence homology with either of these proteins making it difficult to assign a function. However, our study of the shortened construct shows clearly that the N terminus is not required for inhibitory activity.

Members of the serpin superfamily inhibit proteases by undergoing a striking conformational change with transition of the proteinase from the upper to the lower pole of the inhibitor. The same transition may also occur in association with point mutations and chaotropic conditions to form inactive latent and polymeric species (16-19). It is thus important to ensure that a conformationally pure sample of the serpin has been obtained. SDS-PAGE of our purified sample showed that Nec migrated as a single band at ~42 kDa. It was confirmed to be Nec by Western blot and mass spectrometric analysis. The final step of the purification process was gel filtration, which resulted in a single peak, demonstrating that our purified product was monomeric. Circular dichroism spectra of our recombinant protein gave a characteristic signature for a sample containing both alpha -helix and beta -sheet secondary structure. This is similar to the profile of other inhibitory serpins such as alpha 1-antitrypsin (21) and suggests the correct folding of purified Nec-Delta N. Circular dichroism readings at 222 nm with temperatures increasing from 20 to 95 °C resulted in a loss of alpha -helical secondary structure at 48.4 ± 0.7 °C, showing that Nec-Delta N is in its stressed, native form. TUG analysis of our sample showed typical unfolding of native Nec-Delta N between 1 and 3 molar urea. Cleavage of the RCL with trypsin resulted in a species with greater stability at higher urea concentrations as a result of loop insertion. Taken together, these results demonstrate successful purification of active Nec-Delta N in its monomeric, native conformation.

The physiological role of an inhibitory serpin is defined by its protease specificity. It is thus important that a study of the spectrum of specificity for Necrotic be carried out. A panel of mammalian proteases was chosen by virtue of each being an easily available, well characterized member of a specific serine protease family. Results from this study show that Necrotic has a relatively promiscuous specificity being able to inhibit members of the elastase, thrombin, and chymotrypsin families. We have shown that Nec-Delta N successfully forms inhibitory complexes with each protease and has significant association rate constants in excess of 104 M-1 s-1 for each. Furthermore, Nec-Delta N failed to form inhibitory complexes with both trypsin and kallikrein, demonstrating that it retained some selectivity. Thus, Necrotic may act in vivo on a number of serine proteases from select protease families, performing a role as a broad-spectrum protease inhibitor.

Recent studies have revealed that mutations of the gene encoding for the serine protease, Psh, repress the nec- phenotype. However, it remains unclear from genetic analysis whether Nec acts as a direct inhibitor of Psh or whether it inhibits an upstream protease which in turn activates Psh or a combination of both. The specificity of chymotrypsin-class serine proteases can be predicted in part based on the composition of the S1 specificity pocket (28). Analysis of the S1 specificity pocket architecture of Persephone, based on key residues 188, 189, 216, 226, and 228 (chymotrypsin numbering) (29, 30) and three-dimensional structure predictions, suggest that it is similar to thrombin-like proteases. This matches well with the inhibitory specificity determined here for Necrotic, strengthening further the proposal of a direct interaction between these proteins in vivo.

This study has shown that Nec exhibits strongest inhibition of proteases with elastase-like specificity with an association rate constant of >105 M-1s-1 for both PPE and HNE proteases. Elastase specificity pockets typically have a Val residue at position 216 (chymotrypsin numbering) distinguishing them from other chymotrypsin class serine proteases in which this position is restricted to a glycine residue (31, 32). It is thereby likely that Nec would have inhibitory activity against Drosophila proteases containing this motif.

Studies of the TLR pathways in mammals have recently uncovered a number of possible roles for serpins. It has also been understood for a long time that antithrombin regulates the blood coagulation cascade by inhibiting the serine proteases thrombin and the thrombin activator, factor Xa. More recent studies have shown that thrombin can also stimulate the release of nitric oxide via NF-kappa B activation (33) and that extracellular antithrombin can also inhibit lipopolysaccharide-induced activation of NF-kappa B via the TLR4 receptor in mammalian cell cultures (34, 35). These reports indicate that the similarity of mammalian and Drosophila innate immune responses may well extend to the extracellular cascades and are strengthened by our finding that Nec can inhibit thrombin activity.

Several considerations should be taken in understanding the results of this study. First, it is possible that Nec-Delta N may lack some of the specificity-determining regions that could be present in the N-terminal extension. Alternatively, the N terminus may alter the rate of Nec association or stoichiometry of inhibition with its target protease by influencing the stability of either the native serpin or of the serpin-protease complex. Resolution of this can only be achieved by further study of the in vivo function of the protein in combination with similar studies of the full-length protein. In addition, because these experiments were conducted using mammalian rather than Drosophila serine proteases, the true target of Nec may have a higher ka value than the association rate constants reported in this study. Moreover, the fly microenvironment is more complex than that used in these in vitro experiments, possibly generating high localized concentrations of both enzyme and inhibitor. It remains likely, however, that the physiological target(s) of Necrotic will have a specificity that is included within the subset of those serine proteases shown to interact in this study.

Overall this study has shown conclusively that Nec has the potential to act as a competent serine protease inhibitor, with a relatively wide range of specificities. This suggests that Nec may have multiple targets in vivo and presents the opportunity to predict physiological targets of Nec based on analysis of the specificity pocket architecture of Drosophila proteases. It has also been demonstrated that the N-terminal extension is not required for inhibitory activity but does not exclude the possibility that it functions to either modify specificity or influence the association rate through altering the stability of Nec. Finally, our data supports the model that Nec inhibits the Toll-gated innate immune response through the direct inhibition of the serine protease, Psh.

    ACKNOWLEDGEMENTS

We thank Dr. Aiwu Zhou of the University of Cambridge, Cambridge, UK, for his help with the TUG-PAGE experiments. We thank Dr. Jean-Marc Reichhart of the Université Louis Pasteur of Strasbourg, France, for the kind gift of the Nec antibody and nec cDNA, for many helpful scientific discussions, and for his review of this paper.

    FOOTNOTES

* This work is supported by the Wellcome Trust and the Medical Research Council (UK). The Cambridge Centre for Proteomics is a Drosophila proteomics facility funded by the Biotechnology and Biological Sciences Research Council Investigating Gene Function Initiative.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Gates Cambridge Fellow.

Dagger Dagger Medical Research Council Career Development Fellow. To whom correspondence should be addressed: Dept. of Biological Sciences, University of Manchester, 2.205 Stopford Bldg., School of Biological Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK. Tel.: 44-0-161-275-5538; Fax: 44-0-161-275-5082; E-mail: tim.dafforn@man.ac.uk.

Published, JBC Papers in Press, October 31, 2002, DOI 10.1074/jbc.M209277200

2 A. Zhou, personal communication.

    ABBREVIATIONS

The abbreviations used are: TLR, Toll-like receptor; Spz, Spätzle; Nec, Necrotic; serpin, SERine Protease INhibitor; Psh, Persephone; RCL, reactive center loop; PPE, porcine pancreatic elastase; HNE, human neutrophil elastase; DTT, dithiothreitol; CD, circular dichroism; TUG, transverse urea gradient; LC, liquid chromatography; SI, stoichiometry of inhibition.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Aderem, A., and Ulevitch, R. J. (2000) Nature 406, 782-787[CrossRef][Medline] [Order article via Infotrieve]
2. Ip, Y. T., Reach, M., Engstrom, Y., Kadalayil, L., Cai, H., Gonzalez-Crespo, S., Tatei, K., and Levine, M. (1993) Cell 75, 753-763[Medline] [Order article via Infotrieve]
3. Horng, T., and Medzhitov, R. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 12654-12658[Abstract/Free Full Text]
4. Letsou, A., Alexander, S., Orth, K., and Wasserman, S. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 810-814[Abstract]
5. Shelton, C. A., and Wasserman, S. A. (1993) Cell 72, 515-525[Medline] [Order article via Infotrieve]
6. Michel, T., Reichhart, J. M., Hoffmann, J. A., and Royet, J. (2001) Nature 414, 756-759[CrossRef][Medline] [Order article via Infotrieve]
7. Green, C., Levashina, E., McKimmie, C., Dafforn, T., Reichhart, J. M., and Gubb, D. (2000) Genetics 156, 1117-1127[Abstract/Free Full Text]
8. Levashina, E. A., Langley, E., Green, C., Gubb, D., Ashburner, M., Hoffmann, J. A., and Reichhart, J. M. (1999) Science 285, 1917-1919[Abstract/Free Full Text]
9. Ligoxygakis, P., Pelte, N., Hoffmann, J. A., and Reichhart, J. M. (2002) Science 297, 114-116[Abstract/Free Full Text]
10. Silverman, G. A., Bird, P. I., Carrell, R. W., Church, F. C., Coughlin, P. B., Gettins, P. G., Irving, J. A., Lomas, D. A., Luke, C. J., Moyer, R. W., Pemberton, P. A., Remold-O'Donnell, E., Salvesen, G. S., Travis, J., and Whisstock, J. C. (2001) J. Biol. Chem. 276, 33293-33296[Free Full Text]
11. Elliott, P. R., Lomas, D. A., Carrell, R. W., and Abrahams, J. P. (1996) Nat Struct Biol 3, 676-681[Medline] [Order article via Infotrieve]
12. Ye, S., Cech, A. L., Belmares, R., Bergstrom, R. C., Tong, Y., Corey, D. R., Kanost, M. R., and Goldsmith, E. J. (2001) Nat Struct Biol 8, 979-983[CrossRef][Medline] [Order article via Infotrieve]
13. Baumann, U., Huber, R., Bode, W., Grosse, D., Lesjak, M., and Laurell, C. B. (1991) J. Mol. Biol. 218, 595-606[Medline] [Order article via Infotrieve]
14. Huntington, J. A., Read, R. J., and Carrell, R. W. (2000) Nature 407, 923-926[CrossRef][Medline] [Order article via Infotrieve]
15. Lawrence, D. A., Ginsburg, D., Day, D. E., Berkenpas, M. B., Verhamme, I. M., Kvassman, J. O., and Shore, J. D. (1995) J. Biol. Chem. 270, 25309-25312[Abstract/Free Full Text]
16. Chang, W. S., and Lomas, D. A. (1998) J. Biol. Chem. 273, 3695-3701[Abstract/Free Full Text]
17. Belorgey, D., Dirrig, S., Amouric, M., Figarella, C., and Bieth, J. G. (1996) Biochem. J. 313, 555-560[Medline] [Order article via Infotrieve], (Pt 2)
18. Sivasothy, P., Dafforn, T. R., Gettins, P. G., and Lomas, D. A. (2000) J. Biol. Chem. 275, 33663-33668[Abstract/Free Full Text]
19. Zhou, A., Faint, R., Charlton, P., Dafforn, T. R., Carrell, R. W., and Lomas, D. A. (2001) J. Biol. Chem. 276, 9115-9122[Abstract/Free Full Text]
20. Carrell, R. W., and Lomas, D. A. (2002) N. Engl. J. Med. 346, 45-53[Free Full Text]
21. Dafforn, T. R., Mahadeva, R., Elliott, P. R., Sivasothy, P., and Lomas, D. A. (1999) J. Biol. Chem. 274, 9548-9555[Abstract/Free Full Text]
22. Bieth, J. G. (1995) Methods Enzymol. 248, 59-84[CrossRef][Medline] [Order article via Infotrieve]
23. Morrison, J. F., and Walsh, C. T. (1988) Adv Enzymol Relat Areas Mol Biol 61, 201-301[Medline] [Order article via Infotrieve]
24. Bieth, J. G. (1984) Adv Exp Med Biol 167, 97-109[Medline] [Order article via Infotrieve]
25. Skinner, R., Abrahams, J. P., Whisstock, J. C., Lesk, A. M., Carrell, R. W., and Wardell, M. R. (1997) J. Mol. Biol. 266, 601-609[CrossRef][Medline] [Order article via Infotrieve]
26. Jin, L., Abrahams, J. P., Skinner, R., Petitou, M., Pike, R. N., and Carrell, R. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14683-14688[Abstract/Free Full Text]
27. Baglin, T. P., Carrell, R. W., Church, F. C., Esmon, C. T., and Huntington, J. A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 11079-11084[Abstract/Free Full Text]
28. Greer, J. (1990) Proteins 7, 317-334[Medline] [Order article via Infotrieve]
29. Czapinska, H., and Otlewski, J. (1999) Eur J Biochem. 260, 571-595[Abstract/Free Full Text]
30. Perona, J. J., and Craik, C. S. (1995) Protein Sci 4, 337-360[Abstract/Free Full Text]
31. Bode, W., Meyer, E., Jr., and Powers, J. C. (1989) Biochemistry 28, 1951-1963[Medline] [Order article via Infotrieve]
32. Solivan, S., Selwood, T., Wang, Z. M., and Schechter, N. M. (2002) FEBS Lett. 512 (1-3), 133-138[CrossRef][Medline] [Order article via Infotrieve]
33. Ryu, J., Pyo, H., Jou, I., and Joe, E. (2000) J. Biol. Chem. 275, 29955-29959[Abstract/Free Full Text]
34. Mansell, A., Reinicke, A., Worrall, D. M., and O'Neill, L. A. (2001) FEBS Lett. 508, 313-317[CrossRef][Medline] [Order article via Infotrieve]
35. Oelschlager, C., Romisch, J., Staubitz, A., Stauss, H., Leithauser, B., Tillmanns, H., and Holschermann, H. (2002) Blood 99, 4015-4020[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.



This Article
Abstract
Full Text (PDF)
All Versions of this Article:
278/8/6175    most recent
M209277200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Robertson, A. S.
Articles by Dafforn, T. R.
Articles citing this Article
PubMed
PubMed Citation
Articles by Robertson, A. S.
Articles by Dafforn, T. R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.